Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
Tag Archive for: financing
Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
Generative AI protein engineering specialist Cradle NV, has raised US$24m in a Series A financing round led by Index Ventures w
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
Dutch VectorY Tx BV has closed one of this yerss largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.
4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.
Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions. Xlife Sciences was among the first to recognize the importance of artificial intelligence in enhancing patient care and outcomes and has built relevant capabilities within its portfolio companies. For early cancer diagnostics, AI resources were pooled in x-diagnostics, which can now unleash its full potential in a clinical context through the transaction. By becoming a new major shareholder in 4D Lifetec, Xlife Sciences adds a leading early cancer diagnostics pioneer to its portfolio network.
Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec says. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.